TNGX Valuation

Tango Therapeutics Inc

Add to Watchlist

Advanced Chart

6.910

+0.16(2.370%)1D

Overview
Forecast
Valuation
Earnings

TNGX Relative Valuation

TNGX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, TNGX is overvalued; if below, it's undervalued.

Historical Valuation

Tango Therapeutics Inc (TNGX) is now in the Fair zone, suggesting that its current forward PS ratio of 26.56 is considered Fairly compared with the five-year average of -5.60. The fair price of Tango Therapeutics Inc (TNGX) is between 3.37 to 8.58 according to relative valuation methord.

Relative Value

Fair Zone

3.37-8.58

Current Price：6.89

Fair

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

4.46

P/B

Median3y

2.48

Median5y

1.79

-18.78

FCF Yield

Median3y

-27.56

Median5y

-22.86

Competitors Valuation Multiple

The average P/S ratio for TNGX's competitors is 26.00, providing a benchmark for relative valuation. Tango Therapeutics Inc Corp (TNGX) exhibits a P/S ratio of 26.56, which is 2.16% above the industry average. Given its robust revenue growth of -16.67%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

TNGX.O

Tango Therapeutics Inc

26.56

Average P/S: 26.00

-16.67%